Ascletis Pharma Management
Management criteria checks 2/4
Ascletis Pharma's CEO is Jinzi Jason Wu, appointed in Apr 2013, has a tenure of 11.67 years. total yearly compensation is CN¥57.67M, comprised of 99.9% salary and 0.1% bonuses, including company stock and options. directly owns 57.06% of the company’s shares, worth $208.47M. The average tenure of the management team and the board of directors is 5.5 years and 6.7 years respectively.
Key information
Jinzi Jason Wu
Chief executive officer
CN¥57.7m
Total compensation
| CEO salary percentage | 99.9% |
| CEO tenure | 11.7yrs |
| CEO ownership | 57.1% |
| Management average tenure | 5.5yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥258m |
| Mar 31 2024 | n/a | n/a | -CN¥202m |
| Dec 31 2023 | CN¥58m | CN¥58m | -CN¥145m |
| Sep 30 2023 | n/a | n/a | -CN¥194m |
| Jun 30 2023 | n/a | n/a | -CN¥243m |
| Mar 31 2023 | n/a | n/a | -CN¥279m |
| Dec 31 2022 | CN¥23m | CN¥22m | -CN¥315m |
| Sep 30 2022 | n/a | n/a | -CN¥246m |
| Jun 30 2022 | n/a | n/a | -CN¥176m |
| Mar 31 2022 | n/a | n/a | -CN¥188m |
| Dec 31 2021 | CN¥20m | CN¥20m | -CN¥199m |
| Sep 30 2021 | n/a | n/a | -CN¥234m |
| Jun 30 2021 | n/a | n/a | -CN¥269m |
| Mar 31 2021 | n/a | n/a | -CN¥239m |
| Dec 31 2020 | CN¥11m | CN¥11m | -CN¥209m |
| Sep 30 2020 | n/a | n/a | -CN¥155m |
| Jun 30 2020 | n/a | n/a | -CN¥100m |
| Mar 31 2020 | n/a | n/a | -CN¥98m |
| Dec 31 2019 | CN¥11m | CN¥11m | -CN¥96m |
Compensation vs Market: Jinzi Jason's total compensation ($USD7.90M) is above average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Jinzi Jason's compensation has increased whilst the company is unprofitable.
CEO
Jinzi Jason Wu (60 yo)
11.7yrs
Tenure
CN¥57,668,000
Compensation
Dr. Jinzi Jason Wu Ph D, is a Founder of Ascletis Pharma Inc and has been its Chairman March 30, 2018 and has been its CEO since April 2013. In 2013, Dr. Wu founded Ascletis BioScience Co., Ltd.a pharmace...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.7yrs | CN¥57.67m | 57.06% $ 208.5m | |
| Senior VP of Operations & Executive Director | no data | CN¥2.85m | 0.12% $ 436.2k | |
| Senior Vice President of Clinical Development Operations | 3.8yrs | no data | no data | |
| Senior Consultant & Head of Discovery | 11.6yrs | no data | no data | |
| Senior Consultant & Chief Medical Advisor | 7.3yrs | no data | no data | |
| Chief Business Officer | 2.5yrs | no data | no data | |
| Company Secretary | 2.3yrs | no data | no data |
5.5yrs
Average Tenure
56yo
Average Age
Experienced Management: ASCL.F's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.8yrs | CN¥57.67m | 57.06% $ 208.5m | |
| Senior VP of Operations & Executive Director | 6.8yrs | CN¥2.85m | 0.12% $ 436.2k | |
| Independent Non-Executive Director | 6.7yrs | CN¥385.00k | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥385.00k | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥385.00k | no data |
6.7yrs
Average Tenure
50yo
Average Age
Experienced Board: ASCL.F's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 19:09 |
| End of Day Share Price | 2024/12/16 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ascletis Pharma Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | China Merchants Securities (HK) Co., Ltd |
| Mingrui Wang | Everbright Securities Co. Ltd. |
| Siao Ye | Everbright Securities Co. Ltd. |